{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"We planned to evaluate the immunologic response to treatment in blood and bone marrow. Two patients were treated on protocol and both came off due to disease progression early in the course of therapy (one patient during cycle 1 and one patient during cycle 3.) As such, there is insufficient data to perform what had been planned in correlative science studies so no samples were analyzed. This study has been stopped and no further patients are being enrolled and no further samples are being collected. No data has been obtained for any immune analysis; therefore no immune or clinical data will be reported on this trial.","groups":[{"description":"* Nivolumab will be given every two weeks\n* The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle\n\nNivolumab: Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.\n\nDC/myeloma fusions/GM-CSF: The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.","id":"OG000","title":"Nivolumab+DC/Myeloma Fusions/GM-CSF"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Two patients were treated on protocol and both came off due to disease progression early in the course of therapy. Both participants did not achieve a defined clinical response. There is insufficient data to perform what had been planned in correlative science studies or in immune analysis. This study has been stopped and no further patients are being enrolled and no further samples are being collected.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Patients Who Develop Immunologic Response to Nivolumab and the DC/MM Fusion Vaccine","type":"PRIMARY","unitOfMeasure":"Participants"}